Compass Therapeutics (NASDAQ:CMPX - Free Report) had its price target lifted by HC Wainwright from $10.00 to $24.00 in a research note released on Friday,Benzinga reports. They currently have a buy rating on the stock.
A number of other equities research analysts have also issued reports on the company. Wedbush reissued an "outperform" rating and set a $8.00 price target on shares of Compass Therapeutics in a research note on Tuesday, April 1st. Leerink Partners upgraded Compass Therapeutics from a "market perform" rating to an "outperform" rating and raised their price target for the company from $4.00 to $6.00 in a research note on Wednesday, April 2nd. Piper Sandler started coverage on shares of Compass Therapeutics in a research note on Wednesday, February 19th. They issued an "overweight" rating and a $12.00 price objective for the company. Leerink Partnrs upgraded Compass Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Tuesday, April 1st. Finally, D. Boral Capital reiterated a "buy" rating and issued a $32.00 price target on shares of Compass Therapeutics in a report on Tuesday, April 1st. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Compass Therapeutics currently has an average rating of "Buy" and an average target price of $13.38.
Check Out Our Latest Analysis on CMPX
Compass Therapeutics Price Performance
Shares of NASDAQ:CMPX traded up $0.02 during trading on Friday, hitting $1.59. The company had a trading volume of 1,118,836 shares, compared to its average volume of 821,651. The stock has a market cap of $219.87 million, a price-to-earnings ratio of -4.30 and a beta of 1.40. The company has a fifty day simple moving average of $2.73 and a two-hundred day simple moving average of $2.11. Compass Therapeutics has a one year low of $0.77 and a one year high of $4.08.
Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01). On average, equities research analysts anticipate that Compass Therapeutics will post -0.36 earnings per share for the current year.
Insider Activity
In related news, insider Jonathan Anderman purchased 20,000 shares of the firm's stock in a transaction on Monday, April 7th. The stock was acquired at an average price of $1.54 per share, with a total value of $30,800.00. Following the completion of the acquisition, the insider now owns 21,000 shares in the company, valued at approximately $32,340. This represents a 2,000.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 28.50% of the company's stock.
Institutional Trading of Compass Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Rhumbline Advisers raised its stake in shares of Compass Therapeutics by 3.1% in the fourth quarter. Rhumbline Advisers now owns 129,116 shares of the company's stock worth $187,000 after purchasing an additional 3,822 shares during the last quarter. Invesco Ltd. raised its position in Compass Therapeutics by 11.3% during the 4th quarter. Invesco Ltd. now owns 39,483 shares of the company's stock worth $57,000 after buying an additional 4,018 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Compass Therapeutics by 2.6% during the 4th quarter. Bank of New York Mellon Corp now owns 237,975 shares of the company's stock valued at $345,000 after acquiring an additional 6,041 shares during the period. ProShare Advisors LLC boosted its holdings in shares of Compass Therapeutics by 49.0% in the 4th quarter. ProShare Advisors LLC now owns 28,722 shares of the company's stock valued at $42,000 after acquiring an additional 9,451 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of Compass Therapeutics by 31.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 46,942 shares of the company's stock worth $69,000 after acquiring an additional 11,326 shares during the period. Institutional investors and hedge funds own 68.43% of the company's stock.
Compass Therapeutics Company Profile
(
Get Free Report)
Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.
Featured Articles
Before you consider Compass Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compass Therapeutics wasn't on the list.
While Compass Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
